Skinvisible (SKVI) EBT Margin Growth (5y) (2015 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) EBT Margin Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.06 Bn | 626.30 Bn | 17.26 Bn |
| 2 | AbbVie | 440.06 Bn | 433.49 Bn | 12.70 Bn |
| 3 | Merck | 364.19 Bn | 357.05 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.45 Bn | 260.76 Bn | 11.24 Bn |
| 5 | Pfizer | 158.40 Bn | 146.70 Bn | 10.94 Bn |
| 6 | Sanofi | 52.57 Bn | 45.19 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.32 Bn | 44.32 Bn | - |
| 8 | Incyte | 24.98 Bn | 20.44 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.15 Bn | 18.49 Bn | 683.80 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -501,713.00 |
| Mar 31, 2026 | -172,983.00 |
| Dec 31, 2025 | -422,734.00 |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | -529,727.00 |
| Mar 31, 2025 | -294,078.00 |
| Dec 31, 2024 | -338,707.00 |
| Sep 30, 2024 | -194,187.00 |
| Jun 30, 2024 | -160,156.00 |
| Mar 31, 2024 | -164,706.00 |
| Dec 31, 2023 | -317,849.00 |
| Sep 30, 2023 | -85,946.00 |
| Jun 30, 2023 | -382,686.00 |
| Mar 31, 2023 | -2.74 Mn |
| Dec 31, 2022 | -813,582.00 |
| Sep 30, 2022 | -359,148.00 |
| Jun 30, 2022 | 151,045.00 |
| Mar 31, 2022 | 321,462.00 |
| Dec 31, 2021 | 188,650.00 |
| Sep 30, 2021 | 269,719.00 |